Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 684 clinical trials
Study of TSR-042 an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody in Participants With Advanced Solid Tumors

This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics …

monoclonal antibodies
bevacizumab
pd-l1
treatment regimen
solid neoplasm
  • 8 views
  • 08 Nov, 2021
  • 189 locations
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are …

pd-l1
bone marrow procedure
measurable disease
lymphoma
primary cancer
  • 392 views
  • 05 Aug, 2021
  • 44 locations
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

measurable disease
primary cancer
lymphoma
dexamethasone
multiple myeloma
  • 11 views
  • 21 Jan, 2022
  • 12 locations
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down syndrome children with ALL (DS-ALL) in an Asia-wide study. The treatment protocol was modified based upon backbone of Taiwan Pediatric Oncology Group (TPOG)-ALL protocol in which risk classification will be guided by level of flow …

daunorubicin
cytarabine
asparaginase
minimal residual disease
lymphoid leukemia
  • 20 views
  • 20 Jun, 2021
  • 10 locations
Durvalumab and Tremelimumab for Pediatric Malignancies

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined

durvalumab
acute leukemia
lymphoma
leukemia
cancer
  • 15 views
  • 12 Jan, 2022
  • 26 locations
A Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Study CC-90010-ST-001 is an open-label, Phase 1a, dose escalation and expansion, First-in-human (FIH) clinical study of CC-90010 in subjects with advanced or unresectable solid tumors and relapsed and/or refractory advanced Non-Hodgkin's lymphoma (NHL). The dose escalation part (Part A) of the study will explore escalating oral doses of CC-90010 to …

carcinoma
treatment regimen
solid neoplasm
b-cell lymphoma
cancer treatment
  • 160 views
  • 27 Aug, 2021
  • 14 locations
A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and NECs) and R/R NHL (MZL, including extranodal MZL [EMZL], splenic MZL [SMZL], nodal MZL [NMZL], and histologic …

solid neoplasm
b-cell lymphoma
cancer treatment
blood transfusion
primary cancer
  • 0 views
  • 08 Jan, 2022
  • 14 locations
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is …

breast cancer
primary cancer
  • 0 views
  • 23 Jan, 2021
  • 7 locations
Analysis of Circulating Tumor Markers in Blood

The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms …

tumor markers
primary cancer
  • 2 views
  • 10 Nov, 2021
  • 2 locations
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

To evaluate MEDI1191 administered intratumorally in sequential and concurrent combination with intravenous durvalumab in patients with solid tumors.

solid tumor
prednisone
solid neoplasm
metastasis
advanced malignant solid tumor
  • 15 views
  • 11 Dec, 2021
  • 15 locations